Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.

被引：1
|
作者：
Hwang, Inhwang
Kang, Jihoon
Yoo, Changhoon
Kim, Kyu-Pyo
Jeong, Jae Ho
Chang, Heung-Moon
Ryoo, Baek-Yeol
机构：
[1] Univ Ulsan, Asan Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.354
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
354
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
    Rapposelli, Ilario Giovanni
    Casadei-Gardini, Andrea
    Vivaldi, Caterina
    Bartolini, Giulia
    Bernardini, Laura
    Passardi, Alessandro
    Frassineti, Giovanni Luca
    Massa, Valentina
    Cucchetti, Alessandro
    BIOMOLECULES, 2021, 11 (06)
  • [22] EFFICACY OF MODIFIED FOLFIRINOX AS SECOND-LINE CHEMOTHERAPY IN METASTATIC PANCREATIC ADENOCARCINOMA AFTER GEMCITABINE PLUS NAB-PACLITAXEL FAILURE
    Ikezawa, Kenji
    Kiyota, Ryosuke
    Takada, Ryoji
    Imai, Toshihiro
    Yutaro, Abe
    Fukutake, Nobuyasu
    Takatoshi, Nawa
    Katayama, Kazuhiro
    Ohkawa, Kazuyoshi
    GASTROENTEROLOGY, 2020, 158 (06) : S527 - S527
  • [23] ANALYSIS OF US REAL WORLD EVIDENCE DATA TO ASSESS AND COMPARE THE EFFECTIVENESS OF TWO CHEMOTHERAPY REGIMENS: FOLFIRINOX VS GEMCITABINE/NAB-PACLITAXEL FOR FIRST LINE METASTATIC PANCREATIC CANCER
    Bochenska, K.
    Galusza, M.
    Hodge, J. P.
    Raupp, M. D.
    Zeng, S.
    VALUE IN HEALTH, 2023, 26 (06) : S364 - S364
  • [24] nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Real life
    Cidon, E. Una
    Alonso, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S109 - S109
  • [25] Efficacy and safety of Nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
    Filipazzi, V.
    Dalu, D.
    Isabella, L.
    Tosca, N.
    Ferrario, S.
    Gambaro, A.
    Somma, L.
    Fasola, C.
    Pellegrini, I.
    Bombonati, G.
    Curcio, R.
    Damiani, E.
    Cattaneo, M. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan
    Maeda, O.
    Yokoyama, Y.
    Yamaguchi, J.
    Ota, A.
    Matsuoka, A.
    Morita, S.
    Inoue, M.
    Mizutani, T.
    Shimokata, T.
    Urakawa, H.
    Mitsuma, A.
    Nagino, M.
    Ando, Y.
    ANNALS OF ONCOLOGY, 2017, 28 : 69 - 69
  • [27] A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
    Wang, Ying
    Camateros, Pierre
    Cheung, Winson Y.
    JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (01) : 62 - 68
  • [28] A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
    Ying Wang
    Pierre Camateros
    Winson Y. Cheung
    Journal of Gastrointestinal Cancer, 2019, 50 : 62 - 68
  • [29] Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P plus GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC)
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Cranmer, Lee D.
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX
    Peixoto, Renata D.
    Ho, Maria
    Renouf, Daniel J.
    Lim, Howard J.
    Gill, Sharlene
    Ruan, Jenny Y.
    Cheung, Winson Y.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (05): : 507 - 511
12345